RT Journal Article
SR Electronic
T1 Long-COVID following mild SARS CoV-2 infection: characteristic T cell alterations and response to antihistamines
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.06.21258272
DO 10.1101/2021.06.06.21258272
A1 Glynne, Paul
A1 Tahmasebi, Natasha
A1 Gant, Vanya
A1 Gupta, Rajeev
YR 2021
UL http://medrxiv.org/content/early/2021/06/07/2021.06.06.21258272.abstract
AB Background Long-COVID is characterised by the emergence of multiple debilitating symptoms following SARS CoV2 infection. Its aetiology is unclear, and it often follows a mild acute illness. Anecdotal reports of gradual clinical responses to histamine receptor antagonists (HRA) suggest a histamine-dependent mechanism distinct from anaphylaxis. Histamine is a paracrine regulator of T-cells: although T-cell perturbations are reported in acute COVID-19, the T-cell landscape in recovered patients and its relationship to long-COVID remains under-explored.Objective To survey T-cell populations in patients recovered from mild COVID-19, comparing those with long-COVID and asymptomatic individuals, and to analyse these data in light of symptoms and response to HRA.Design Prospective observational cohort study.Setting Single-site outpatient clinicParticipants 65 (87 to 408 days post mild COVID-19). None had sought treatment for acute COVID-19. 16 recovered uneventfully (asymptomatic group), 49 presented with long-COVID (symptomatic group), of whom 25 received HRA.Measurements Structured long-COVID symptom questionnaire; quantification of T-cell subsets using a standard diagnostic assay.Results HRA significantly reduced mean symptom burden. T-cell profiles distinguished asymptomatic and long-COVID groups, but did not predict response to HRA. Long-COVID patients had reduced CD4+ and CD8+ effector memory (EM) cells and increased PD-1 expression on central memory (CM) cells. Asymptomatic controls had reduced CD8+ EM cells and increased CD28 expression on CM cells.Conclusion HRA reduce long-COVID symptoms. T-cell perturbations persist for up to 400 days following mild acute COVID-19 irrespective of long-COVID symptoms.Limitations Preliminary, single health system study.Primary Funding Source Philanthropic donations from The Dominvs Group and Sir Peter WoodCompeting Interest StatementThe authors have declared no competing interest.Funding StatementPhilanthropic donations from The Dominvs Group and Sir Peter Wood None of the authors received personal funding for this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was sponsored by HCA healthcare, who provided IRB approvalAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAny data that DO NOT contain patient identifying information are available on request